RSS

Staphefekt

Antimicrobial resistance (AMR) has been heralded as “one of the biggest health threats facing mankind” by the O’Neill review. EPM looks at five ways in which the pharmaceutical sector is fighting this threat more

News

Johan Frieling has recently been appointed as the new chief medical officer of Micreos. EPM talks to him about his experience in the pharmaceutical sector and the company’s new antibiotic alternative, Staphefekt more

Opinion

Micreos, a biotech company has secured £9.3m (€12m) for the global development of new products containing Staphefekt, an alternative to antibiotics more

News